BUSINESS COMBINATION AGREEMENT BY AND AMONG THERAPEUTICS ACQUISITION CORP., BODHI MERGER SUB, INC., AND POINT BIOPHARMA INC. DATED AS OF MARCH 15, 2021Business Combination Agreement • March 18th, 2021 • Therapeutics Acquisition Corp. • Blank checks • Delaware
This BUSINESS COMBINATION AGREEMENT (this "Agreement"), dated as of March 15, 2021, is made by and among Therapeutics Acquisition Corp., a Delaware corporation ("RACA") d/b/a Research Alliance Corp. I, Bodhi Merger Sub, Inc., a Delaware corporation ("Merger Sub"), and Point Biopharma Inc., a Delaware corporation (the "Company"). RACA, Merger Sub and the Company shall be referred to herein from time to time collectively as the "Parties". Capitalized terms used but not otherwise defined herein have the meanings set forth in Section 1.1.
SPONSOR LETTER AGREEMENTSponsor Letter Agreement • March 18th, 2021 • Therapeutics Acquisition Corp. • Blank checks
This SPONSOR LETTER AGREEMENT (this “Agreement”), dated as of March 14, 2021, is made by and among Therapeutics Acquisition Holdings LLC, a Delaware limited liability company (the “Sponsor”), the other holders of RACA Class B Common Stock set forth on Schedule I hereto (the “Other Class B Holders”, and together with the Sponsor, collectively, the “Class B Holders”), Therapeutics Acquisition Corp. (d/b/a Research Alliance Corp.), a Delaware corporation (“RACA”), and Point Biopharma Inc., a Delaware corporation (the “Company”). The Sponsor, the Other Class B Holders, RACA and the Company shall be referred to herein from time to time collectively as the “Parties”. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Business Combination Agreement (as defined below).
